Apogee Therapeutics stock delisted from Nasdaq

Apogee Therapeutics, Inc. (APGE) is having its common stock removed from listing and registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934.

Rhea-AI Filing Summary

Apogee Therapeutics, Inc. (APGE) is having its common stock removed from listing and registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934. Nasdaq filed a Form 25, certifying it has complied with its own rules and SEC Rule 12d2-2 for striking the common stock from listing and withdrawing its registration on the exchange.

Key Terms

Form 25, Section 12(b), 17 CFR 240.12d2-2(b), 17 CFR 240.12d2-2(c)

4 terms

Form 25 regulatory

"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION"

A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.

Section 12(b) regulatory

"registration under Section 12(b) of the Securities Exchange Act of 1934"

Section 12(b) of the U.S. Securities Exchange Act requires securities listed on a national stock exchange to be registered with the U.S. Securities and Exchange Commission (SEC) and to follow regular public reporting and disclosure rules. For investors, a 12(b) listing generally means more routine financial updates, regulatory oversight and easier buying and selling—like a storefront that must display its inventory and prices, making it simpler to inspect and trade the product.

17 CFR 240.12d2-2(b) regulatory

"Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied"

17 CFR 240.12d2-2(c) regulatory

"requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Apogee Therapeutics (APGE) disclose in this Form 25 filing?

The filing states that Nasdaq Stock Market LLC filed Form 25 to remove Apogee Therapeutics’ common stock from listing and registration under Section 12(b) of the Exchange Act, after certifying compliance with its own rules and SEC Rule 12d2-2.

Which Apogee Therapeutics (APGE) security is affected by this Form 25?

The Form 25 covers Apogee Therapeutics, Inc. common stock. The notice specifies “Common Stock” as the class of securities subject to removal from listing and registration on the Nasdaq Stock Market LLC.

Who filed the Form 25 related to Apogee Therapeutics (APGE)?

The Form 25 is filed by Nasdaq Stock Market LLC. Nasdaq certifies that it has reasonable grounds to believe it meets all requirements for filing Form 25 and has complied with its rules and Rule 12d2-2 governing removal from listing and registration.

Under what SEC rule is Apogee Therapeutics’ (APGE) common stock being removed from listing?

The removal is made under SEC Rule 12d2-2, cited as 17 CFR 240.12d2-2(b) and 17 CFR 240.12d2-2(c), which govern exchange-initiated striking of a listing and issuer-initiated voluntary withdrawal from listing and registration.

What law governs the Form 25 filed for Apogee Therapeutics (APGE)?

The Form 25 is filed under the Securities Exchange Act of 1934, specifically concerning removal from listing and/or registration under Section 12(b) for Apogee Therapeutics’ common stock on Nasdaq.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 10:37 AM EDT Accepted by SEC EDGAR 09/03/2026 - 10:37 AM EDT Learn about SEC filing dates

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-41740

Issuer:	Apogee Therapeutics, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	221 Crescent St
	Building 17, Suite 102b
	Waltham	MASSACHUSETTS	02453
Telephone number:					(650) 394-5230

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-09-03	By	Tara Petta		AVP
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.